Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 3
1966 5
1967 2
1968 1
1969 4
1970 1
1972 1
1973 2
1974 1
1975 2
1976 2
1977 2
1980 1
1981 2
1982 3
1983 2
1986 1
1987 2
1989 2
1990 1
1992 1
1993 1
1994 2
1995 1
1996 1
1997 3
1998 4
1999 3
2000 1
2001 2
2002 7
2003 2
2004 7
2005 5
2006 5
2007 10
2008 16
2009 14
2010 17
2011 23
2012 22
2013 23
2014 32
2015 24
2016 34
2017 39
2018 45
2019 29
2020 37
2021 37
2022 39
2023 15
2024 31
2025 26
2026 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

551 results

Results by year

Filters applied: . Clear all
Page 1
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, Ralston SH, Walters M, Robertson M, De Caterina R, Findlay E, Perez-Ruiz F, McMurray JJV, MacDonald TM; FAST Study Group. Mackenzie IS, et al. Lancet. 2020 Nov 28;396(10264):1745-1757. doi: 10.1016/S0140-6736(20)32234-0. Epub 2020 Nov 9. Lancet. 2020. PMID: 33181081 Free article. Clinical Trial.
METHODS: We did a prospective, randomised, open-label, blinded-endpoint, non-inferiority trial of febuxostat versus allopurinol in patients with gout in the UK, Denmark, and Sweden. ...This study is registered with the EU Clinical Trials Registe …
METHODS: We did a prospective, randomised, open-label, blinded-endpoint, non-inferiority trial of febuxostat versus allopurinol …
Efficacy and Safety of Allopurinol and Febuxostat in Patients With Gout and CKD: Subgroup Analysis of the STOP Gout Trial.
Helget LN, Davis-Karim A, O'Dell JR, Mikuls TR, Newcomb JA, Androsenko M, Brophy MT, England BR, Ferguson R, Pillinger MH, Neogi T, Wu H, Palevsky PM. Helget LN, et al. Am J Kidney Dis. 2024 Nov;84(5):538-545. doi: 10.1053/j.ajkd.2024.04.017. Epub 2024 Jun 19. Am J Kidney Dis. 2024. PMID: 38906504 Clinical Trial.
PLAIN-LANGUAGE SUMMARY: The STOP Gout Trial was a multicenter, randomized, double-blind, noninferiority, comparative effectiveness trial, which found that allopurinol was noninferior to febuxostat in gout flare prevention and that both medicatio …
PLAIN-LANGUAGE SUMMARY: The STOP Gout Trial was a multicenter, randomized, double-blind, noninferiority, comparative effective …
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N. Schumacher HR Jr, et al. Arthritis Rheum. 2008 Nov 15;59(11):1540-8. doi: 10.1002/art.24209. Arthritis Rheum. 2008. PMID: 18975369 Clinical Trial.
OBJECTIVE: To compare the urate-lowering efficacy and safety of febuxostat, allopurinol, and placebo in a large group of subjects with hyperuricemia and gout, including persons with impaired renal function. ...The primary reasons for withdrawal were similar across g …
OBJECTIVE: To compare the urate-lowering efficacy and safety of febuxostat, allopurinol, and placebo in a large group of subjects wit …
Comparative Effectiveness of Allopurinol and Febuxostat in Gout Management.
O'Dell JR, Brophy MT, Pillinger MH, Neogi T, Palevsky PM, Wu H, Davis-Karim A, Newcomb JA, Ferguson R, Pittman D, Cannon GW, Taylor T, Terkeltaub R, Cannella AC, England BR, Helget LN, Mikuls TR. O'Dell JR, et al. NEJM Evid. 2022 Mar;1(3):10.1056/evidoa2100028. doi: 10.1056/evidoa2100028. Epub 2022 Feb 3. NEJM Evid. 2022. PMID: 35434725 Free PMC article.
This double-blind noninferiority trial examined these issues. METHODS: Participants with gout and hyperuricemia (with at least 33% having stage 3 chronic kidney disease) were randomly assigned to allopurinol or febuxostat in this 72-week trial, with do …
This double-blind noninferiority trial examined these issues. METHODS: Participants with gout and hyperuricemia (with at least …
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. Becker MA, et al. N Engl J Med. 2005 Dec 8;353(23):2450-61. doi: 10.1056/NEJMoa050373. N Engl J Med. 2005. PMID: 16339094 Free article. Clinical Trial.
BACKGROUND: Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, is a potential alternative to allopurinol for patients with hyperuricemia and gout. METHODS: We randomly assigned 762 patients with gout and with serum urate concentrations of …
BACKGROUND: Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, is a potential alternative to allopurinol for pati …
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.
White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L; CARES Investigators. White WB, et al. N Engl J Med. 2018 Mar 29;378(13):1200-1210. doi: 10.1056/NEJMoa1710895. Epub 2018 Mar 12. N Engl J Med. 2018. PMID: 29527974 Free article. Clinical Trial.
BACKGROUND: Cardiovascular risk is increased in patients with gout. We compared cardiovascular outcomes associated with febuxostat, a nonpurine xanthine oxidase inhibitor, with those associated with allopurinol, a purine base analogue xanthine oxidase inhibitor, in …
BACKGROUND: Cardiovascular risk is increased in patients with gout. We compared cardiovascular outcomes associated with febuxostat, a …
Update on gout management: what is old and what is new.
Afinogenova Y, Danve A, Neogi T. Afinogenova Y, et al. Curr Opin Rheumatol. 2022 Mar 1;34(2):118-124. doi: 10.1097/BOR.0000000000000861. Curr Opin Rheumatol. 2022. PMID: 34907116 Free PMC article. Review.
There is improved understanding of risk factors for allopurinol hypersensitivity syndrome and well tolerated use of allopurinol in chronic kidney disease. Trial data have provided new insights regarding cardiovascular risk with febuxostat. Several new drug th …
There is improved understanding of risk factors for allopurinol hypersensitivity syndrome and well tolerated use of allopurinol …
Hepatic Safety of Febuxostat and Allopurinol for Gout Patients: A Systematic Review of Randomized Controlled Trial.
Dewi C, Puspita F, Puspitasari IM, Zakiyah N. Dewi C, et al. Ther Clin Risk Manag. 2023 Sep 18;19:731-743. doi: 10.2147/TCRM.S424598. eCollection 2023. Ther Clin Risk Manag. 2023. PMID: 37744559 Free PMC article. Review.
The inclusion criteria were to review all randomized controlled trials (RCT) that compared allopurinol and febuxostat for adult gout patients that had an assessment of liver function outcomes. ...CONCLUSION: Our analysis concluded that adult gout patie …
The inclusion criteria were to review all randomized controlled trials (RCT) that compared allopurinol and febuxostat for adul …
Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial.
Stamp L, Horne A, Mihov B, Drake J, Haslett J, Chapman PT, Frampton C, Dalbeth N. Stamp L, et al. Ann Rheum Dis. 2023 Dec;82(12):1626-1634. doi: 10.1136/ard-2023-224731. Epub 2023 Aug 31. Ann Rheum Dis. 2023. PMID: 37652661 Clinical Trial.
OBJECTIVES: To determine whether placebo is non-inferior to low-dose colchicine for reducing gout flares during the first 6 months of allopurinol using the 'start-low go-slow' dose approach. ...CONCLUSIONS: Placebo is not non-inferior to colchicine in prevention of …
OBJECTIVES: To determine whether placebo is non-inferior to low-dose colchicine for reducing gout flares during the first 6 months of …
Comparison of Gout Flares With the Initiation of Treat-to-Target Allopurinol and Febuxostat: A Post-Hoc Analysis of a Randomized Multicenter Trial.
Barry A, Helget LN, Androsenko M, Wu H, Kramer B, Newcomb JA, Brophy MT, Davis-Karim A, England BR, Ferguson R, Pillinger MH, Neogi T, Palevsky PM, Merriman TR, O'Dell JR, Mikuls TR. Barry A, et al. Arthritis Rheumatol. 2024 Oct;76(10):1552-1559. doi: 10.1002/art.42927. Epub 2024 Jul 15. Arthritis Rheumatol. 2024. PMID: 38925627 Free PMC article. Clinical Trial.
OBJECTIVE: Initiating urate-lowering therapy (ULT) in gout can precipitate arthritis flares. There have been limited comparisons of flare risk during the initiation and escalation of allopurinol and febuxostat, administered as a treat-to-target strategy with optimal …
OBJECTIVE: Initiating urate-lowering therapy (ULT) in gout can precipitate arthritis flares. There have been limited comparisons of f …
551 results